# US 2014/0348836 A1 · Anti-cd40 antibodies, uses and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0348836 A1
- Document ID: US20140348836A1
- Status: Published application
- Kind: A1
- Application number: 14/342,141
- Filed: 2012-09-05
- Published: 2014-11-27
- Earliest claimed: 2011-09-05
- Assignees: Alligator Bioscience AB
- Inventors: Peter Bo Joakim Ellmark; Eva Maria Dahlen
- Web page: https://patentgrep.com/patent/US20140348836A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 49/00: Preparations for testing in vivo
- A61K 51/103: {against receptors for growth factors or receptors for growth regulators}
- A61K 51/1096: {radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10−10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.

## Claims

### Claim 1

An antibody or an antigen-binding fragment thereof with multivalent binding specificity for CD40,
or a variant, fusion or derivative of said antibody or antigen-binding fragment, or a fusion of a said variant or derivative thereof, which retains the multivalent binding specificity for the CD40,
wherein the potency of the antibody, antigen-binding fragment, or fusion, variant or derivative thereof, for dendritic cell activation is higher than, or is equal to, its potency for B cell activation and/or wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10−10 M.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, antigen-binding fragment, variant, fusion or derivative thereof is capable of a direct apoptotic effect on tumour cells and an indirect immune cell-mediated cytotoxic effect on the tumour cells.

### Claim 4 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, antigen-binding fragment, variant, fusion or derivative thereof has a two-fold greater potency for the activation of dendritic versus B cells, for example, at least three-fold, four-fold, five-fold, six-fold, seven-fold, eight-fold, nine-fold, ten-fold or more greater potency for the activation of dendritic cells.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, antigen-binding fragment, variant, fusion or derivative thereof has improved binding specificity for CD40 relative to that of the B44 antibody.

### Claim at position 8

8-10. (canceled)

### Claim 11 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, antigen-binding fragment, variant, fusion or derivative thereof has an affinity (KD) for CD40 in the range 1.0×10−10 M to 1×10−11 M and an on-rate (ka) for CD40 in the range 2.7 106 to 1×107 Ms.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, comprises or consists of an intact antibody.

### Claim 14 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, comprises or consists of an antigen-binding fragment selected from the group consisting of: an Fv fragment (such as a single chain Fv fragment, or a disulphide-bonded Fv fragment), and a Fab-like fragment (such as a Fab fragment; a Fab′ fragment or a F(ab)2 fragment).

### Claim at position 13

15-17. (canceled)

### Claim 18 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, antigen-binding fragment, variant, fusion or derivative thereof, is human or humanised.

### Claim 19 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, fragment, variant, fusion or derivative comprises a variable light chain (VL) in which CDR1 comprises or consists of the amino acid sequence of SEQ ID NO: 1, 2, or 3, wherein:
(a)
[SEQ ID NO: 1]
CTGSX1SNIGX2VY
wherein:
X1 is S or T; and
X2 is K or H or D or G or N;
(b)
[SEQ ID NO: 2]
X3NINRPS
wherein:
X3 is G or R; or
(c)
[SEQ ID NO: 3]
CAAWDX4X5X6X7GLX8
wherein:
X4 is D or S or E or G or K; and
X5 is S or T or G; and
X6 is L or S or T or L or I; and
X7 is S or T or L; and
X8 is V or L.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 19)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 19 wherein the antibody, fragment, variant, fusion or derivative comprises:
(a) a variable light chain (VL) in which CDR1 comprises or consists of an amino acid sequence selected from the group consisting of:
[SEQ ID NO: 4]
CTGSTSNIGAGYKVY;
[SEQ ID NO: 5]
CTGSSSNIGAGYHVY;
[SEQ ID NO: 6]
CTGSSSNIGAGYKVY;
[SEQ ID NO: 7]
CTGSSSNIGAGYDVY;
[SEQ ID NO: 8]
CTGSSSNIGAGYGVY;
and
[SEQ ID NO: 9]
CTGSSSNIGAGYNVY,
(b) a variable light chain (VL) in which CDR2 comprises or consists of an amino acid sequence selected from the group consisting of:
[SEQ ID NO: 10]
GNINRPS;
and
[SEQ ID NO: 11]
RNINRPS,
and/or
(c) a variable light chain (VL) in which CDR3 comprises or consists of an amino acid sequence selected from the group consisting of:
[SEQ ID NO: 12]
CAAWDDSLSGLV;
[SEQ ID NO: 13]
CAAWDSSSSGLV;
[SEQ ID NO: 14]
CAAWDESITGLV;
[SEQ ID NO: 15]
CAAWDGSLLGLV;
[SEQ ID NO: 16]
CAAWDGTLTGLL;
[SEQ ID NO: 17]
CAAWDKSISGLV;
and
[SEQ ID NO: 18]
CAAWDGGLLGLV.

### Claim at position 19

23-25. (canceled)

### Claim 26 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, fragment, variant, fusion or derivative comprises a variable light chain (VL) comprising an amino acid sequence selected from the group consisting of:
SEQ ID NO:19; SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22;
SEQ ID NO:23; SEQ ID NO:24; SEQ ID NO:25; SEQ ID NO:26;
and SEQ ID NO:27.

### Claim 27 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, fragment, variant, fusion or derivative comprises:
(a) a variable heavy chain (VH) in which CDR1 comprises or consists of the amino acid sequence of:
[SEQ ID NO: 28]
GFTFSTYGMH,
(b) a variable heavy chain (VH) in which CDR2 comprises or consists of the amino acid sequence of:
[SEQ ID NO: 29]
GKGLEWLSYISGGSSYIFYADSVRGR,
and/or
(c) a variable heavy chain (VH) in which CDR3 comprises or consists of the amino acid sequence of:
[SEQ ID NO: 30]
CARILRGGSGMDL.

### Claim at position 22

28-30. (canceled)

### Claim 31 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, fragment, variant, fusion or derivative comprises a variable heavy chain (VH) comprising an amino acid sequence selected from the group consisting of:
SEQ ID NO:31; SEQ ID NO:32; SEQ ID NO:33; SEQ ID NO:34;
SEQ ID NO:35; SEQ ID NO:36; SEQ ID NO:37; SEQ ID NO:38;
and SEQ ID NO:39.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, fragment, variant, fusion or derivative comprises a variable light chain (VL) and a variable heavy chain (VH) comprising the following amino acid sequences:
(i) SEQ ID NO:19 and SEQ ID NO:31; or
(ii) SEQ ID NO:20 and SEQ ID NO:32; or
(iii) SEQ ID NO:21 and SEQ ID NO:33; or
(iv) SEQ ID NO:22 and SEQ ID NO:34; or
(v) SEQ ID NO:23 and SEQ ID NO:35; or
(vi) SEQ ID NO:24 and SEQ ID NO:36; or
(vii) SEQ ID NO:25 and SEQ ID NO:37; or
(viii) SEQ ID NO:26 and SEQ ID NO:38; or
(ix) SEQ ID NO:27 and SEQ ID NO:39.

### Claim 34 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, fragment, variant, fusion or derivative binds to an epitope within the first domain (D1) of CD40.

### Claim 35 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 wherein the antibody, fragment, variant, fusion or derivative compete for binding to CD40 with one or more of the antibodies in Table A.

### Claim 36 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 which comprises an antibody Fc-region.

### Claim 37 (depends on 36)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 36 wherein the Fc-region is from an IgG1 antibody.

### Claim 38 (depends on 36)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 36 wherein the Fc-region comprises or consists of the amino acid sequence of SEQ ID NO: 62.

### Claim 39

(canceled)

### Claim 40 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 further comprising a cytotoxic moiety.

### Claim at position 33

41-49. (canceled)

### Claim 50 (depends on 1)

An antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, according to claim 1 further comprising a readily-detectable moiety.

### Claim at position 35

51-60. (canceled)

### Claim 61 (depends on 1)

A pharmaceutical composition comprising an effective amount of an antibody or antigen-binding fragment, or variant, fusion or derivative thereof, as defined in claim 1, and a pharmaceutically-acceptable buffer, excipient, diluent or carrier.

### Claim at position 37

62-68. (canceled)

### Claim 69 (depends on 1)

A method for treating an individual with cancer, the method comprising the step of administering to an individual in need thereof an effective amount of: an antibody or antigen-binding fragment, or a variant, fusion or derivative thereof, as defined in claim 1.

### Claim at position 39

70-75. (canceled)
